university website

J.J. Swen (Jesse), M. Nijenhuis (M.), van Rhenen, M. (Mandy), de Boer-Veger, N.J. (Nienke J.), Buunk, A.-M. (Anne-Marie), Houwink, E.J.F. (Elisa J.F.), H. Mulder (Hans), G.A. Rongen (Gerard), van Schaik, R.H.N. (Ron H.N.), J. van der Weide (Jan), et al. B. Wilffert (Bob), V.H.M. Deneer (V. H M) and H.J. Guchelaar (Henk Jan)

2018-05-01

Pharmacogenetic Information in Clinical Guidelines: The European Perspective

Publication

Publication

Clinical Pharmacology and Therapeutics , Volume 103 - Issue 5 p. 795- 801

Surveys among pharmacists and physicians show that these healthcare professionals have successfully adopted the concept of pharmacogenomics (PGx).1-3 In addition, patients are willing to consent to participate in PGx implementation studies.4 However, the surveys also show that healthcare professionals do not frequently order or recommend a PGx test.1,2 Among others, a frequently perceived hurdle for clinical uptake of PGx is the availability of guidelines translating PGx test results into clinical actions for individual patients.5,6.

Additional Metadata
Persistent URL doi.org/10.1002/cpt.1049, hdl.handle.net/1765/111220
Journal Clinical Pharmacology and Therapeutics
Grant This work was funded by the European Commission 7th Framework Programme; grant id h2020/668353 - Ubiquitous Pharmacogenomics (U-PGx): Making actionable pharmacogenomic data and effective treatment optimization accessible to every European citizen (U-PGx), This work was funded by the European Commission 7th Framework Programme; grant id h2020/668353 - Ubiquitous Pharmacogenomics (U-PGx): Making actionable pharmacogenomic data and effective treatment optimization accessible to every European citizen (U-PGx)
Organisation Department of Clinical Chemistry


User Publication Person Organisation Collection
Close